Business Context and Reporting Period
This Form 8-K is filed by Knight Knox Development Corp. (not Artelo Biosciences, Inc.) for the reporting period ending September 1, 2016. The registrant is incorporated in Nevada with principal executive offices in London, England.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate transaction event.
Material Changes
- Termination of Agreement: The company terminated a binding letter of intent (LOI) previously entered into on July 13, 2016.
- Transaction Details: The LOI concerned a triangular merger involving Knight Knox Development Corp., GiftBoxCenter, LLC, and GBC Sub Inc.
- Process: Verbal notification of termination was provided to GiftBoxCenter on September 1, 2016, followed by a written termination notice received from GiftBoxCenter.
- Disputes: The filing explicitly states there were no disagreements between the parties regarding the termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or specific risk factors beyond the cessation of the proposed merger. No unusual items or contingencies were disclosed.
Investor Verification Checklist
- Verify the correct registrant name is Knight Knox Development Corp., as the input metadata referenced Artelo Biosciences, Inc.
- Confirm the status of the July 13, 2016, binding letter of intent with GiftBoxCenter, LLC.
- Review subsequent filings to determine if the company has entered into new merger agreements or strategic partnerships.
- Check the company's latest 10-K or 10-Q for actual financial performance data, as this 8-K contains none.